Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease

Loh, Chee Hong; Donohue, James F.; Ohar, Jill A.

doi:10.1517/14740338.2015.998196

Cited by 9 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-acting agents formoterol fumarate and arformoterol tartrate, which currently serve as the mainstays of nebulized maintenance therapy for COPD, have demonstrated a significant reduction in FEV 1 , but there are no head-to-head clinical trials comparing the efficacy and safety of these two nebulized therapies. While tolerance (tachyphylaxis) to the bronchodilator effect of arformoterol has been reported in clinical trials, 40 , 44 , 87 no other clinical manifestations of tolerance were evident. In contrast, clinical trials with nebulized formoterol failed to show any evidence of tolerance, as indicated by maintained FEV 1 AUC and reduced rescue inhaler use with up to 12 weeks of treatment.…”

Section: Discussionmentioning

confidence: 92%

“…Nebulized arformoterol tartrate is of potential benefit to patients with hyperinflation and low PIFR. 40 Arformoterol is safe in combination therapy with certain handheld inhalers (eg, ICS, long-acting muscarinic antagonists [LAMAs], and short-acting β 2 -agonists [SABAs]), but it is contraindicated in combination with a handheld inhaled LABA (alone or in combination with an ICS or an LAMA). A 12-month Phase 4 trial found no increased risk of respiratory death or COPD exacerbation-related hospitalizations with nebulized arformoterol treatment.…”

Section: Nebulized Pharmacologic Therapymentioning

confidence: 99%

See 1 more Smart Citation

A review of nebulized drug delivery in COPD

Tashkin¹

2016

COPD

View full text Add to dashboard Cite

Current guidelines recommend inhaled pharmacologic therapy as the preferred route of administration for treating COPD. Bronchodilators (β2-agonists and antimuscarinics) are the mainstay of pharmacologic therapy in patients with COPD, with long-acting agents recommended for patients with moderate to severe symptoms or those who are at a higher risk for COPD exacerbations. Dry powder inhalers and pressurized metered dose inhalers are the most commonly used drug delivery devices, but they may be inadequate in various clinical scenarios (eg, the elderly, the cognitively impaired, and hospitalized patients). As more drugs become available in solution formulations, patients with COPD and their caregivers are becoming increasingly satisfied with nebulized drug delivery, which provides benefits similar to drugs delivered by handheld inhalers in both symptom relief and improved quality of life. This article reviews recent innovations in nebulized drug delivery and the important role of nebulized therapy in the treatment of COPD.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Nebulized Pharmacologic Therapymentioning

confidence: 99%

A review of nebulized drug delivery in COPD

Tashkin¹

2016

COPD

View full text Add to dashboard Cite

show abstract

“…The N -formylated compounds, on the other hand, have been less explored, probably because of their more challenging preparation [ 5 ]. However sporadic a chemical structure, some noteworthy drugs are available in the market, namely Formoterol [ 6 ] and Arformoterol [ 7 ], for pulmonary diseases and Orlistat for the treatment of obesity [ 8 ] ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

N-Formylsaccharin: A Sweet(able) Formylating Agent in Mechanochemistry

et al. 2022

View full text Add to dashboard Cite

The acylation of amines has always attracted a deep interest as a synthetic route due to its high versatility in organic chemistry and biochemical processes. The purpose of this article is to present a mechanochemical acylation procedure based on the use of acyl-saccharin derivatives, namely N-formylsaccharin, N-acetylsaccharin, and N-propionylsaccharin. This protocol furnishes a valuable solvent-free alternative to the existing processes and aims to be highly beneficial in multi-step procedures due to its rapid and user-friendly workup.

show abstract

“…The N-formylated compounds, instead, have been less explored, probably due to some handling complications in their preparation. However, this does not suggest that their importance is negligible: as a matter of fact, some noteworthy drugs are available in the market, namely Formoterol and Arformoterol [5,6] for pulmonary diseases and Orlistat for the treatment of obesity [7] Fig. 1.…”

Section: Introductionmentioning

confidence: 99%

N-Formylsaccharin: A Sweet(able) Formylating Agent in Mechanochemistry

Cuccu¹,

Basoccu²,

Fattuoni³

et al. 2022

Preprint

View full text Add to dashboard Cite

The acylation of amines has always attracted a deep interest as a synthetic route due to its high versatility in organic chemistry and biochemical processes. The purpose of this article is to depict a mechanochemical acylation procedure based on the use of acyl-saccharin derivatives, namely N-formylsaccharin, N-acetylsaccharin and N-propionylsaccharin. This protocol furnishes a valuable solventless alternative to the existing processes and aims to be highly beneficial in multi-step procedures due to its rapid and user-friendly workup.

show abstract

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease

Cited by 9 publications

References 34 publications

A review of nebulized drug delivery in COPD

A review of nebulized drug delivery in COPD

N-Formylsaccharin: A Sweet(able) Formylating Agent in Mechanochemistry

N-Formylsaccharin: A Sweet(able) Formylating Agent in Mechanochemistry

Contact Info

Product

Resources

About